IO Biotech

IOBT

Biotechnology · Healthcare

Price

$0.01

-0.00 (-27.59%)

Market Cap

$885,690

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Share count rising — dilution

+470.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 11.5M (2020) → 65.9M (2024)

Winston Score History

The full picture

IO Biotech is a clinical-stage biotechnology company focused on developing cancer treatments. Its main approach uses the body's own immune system to fight tumors, a method called immunotherapy. The company's lead drug candidate, IO102-IO103, targets melanoma and other solid tumors, and is being tested in clinical trials rather than sold to patients yet.

IO Biotech does not generate meaningful revenue because its drugs are still in development and not yet approved for sale. The company is headquartered in Copenhagen, Denmark, with operations also in the United States, and it funds itself primarily through cash raised from investors. The biggest risk the company faces is clinical and regulatory: if its drug candidates fail in trials or do not receive approval from the FDA or other regulators, the company would need to raise more money or could run out of funding entirely.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+63.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$71M/ year

↑ Rising (+5% vs prior year)

R&D investment increasing — building for the future

Insider Activity

16.1%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~5 months

$31M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

IO Biotech has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-3890.6%

Weak — -3890.6% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

1.60

Elevated debt (1.60)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial